top of page

Who we are

Capcyte Biotherapeutics

Capcyte is a McGill spin-off that originated from the Stem Cell Bioprocessing Hoesli Lab in 2022. With our team of chemical engineers and our patented surface modification technology, Capcyte has one core mission: pushing the boundaries of cardiovascular care. Originally designed to address the lack of hemocompatibility of cardiovascular implants, our technology has the potential for broad implications in many other fields, including therapeutic cell culture.

Screen Shot 2023-09-07 at 12.54.13 PM.png

Our Team

Our Story

2015

CIHR Open Operating Grant to develop biomimetic stent 

2020

US provisional patent submission (63/051,608)

2020

TechAccelR grant (McGill Engine, $7,500)

2022

NSERC Idea to Innovation Phase 1 for the development of functionnalized microcarriers

2022

Incorporation of Capcyte Biotherapeutics Inc. in Canada

2023

McGill Innovation Fund (Develop stage, $50,000)

Second TechAccelR grant (McGill Engine, $7,500)

2023

Exclusive license agreement with McGill and Laval University

Awards

TECHACCELR GRANT 2020, 2023

TechAccelR Grants support McGill Faculty of Engineering tenure-track professors by enabling them to accelerate their technology that is reported as an invention but needs further validation prior to commercialization. A grant of $7500 and a business mentor was awarded to us both times.

DiPIERRO FELLOWSHIP AWARD 2023

The Innovation Fellowship Program supports the recipient on the development of a technology for commercialization and allow to gain further knowledge and experience in business and technology commercialization. In addition to funding, teams are matched with an experienced mentor.

McGill INNOVATION FUND 2023

The MIF is a University-wide funding competition for projects that are based on technology developed by McGill researchers. The Develop stage award ($50,000) is meant for projects in their development path and working on their commercial prototype.

Get in touch

3610 University street

Montreal, QC H3A 0C5

  • LinkedIn

Thanks for submitting!

bottom of page